Living Near Golf Courses May Double Parkinson's Risk, Study Finds
Potentially Due to Groundwater Contamination
The case-control study, recently published in
Researchers looked at how close the individuals lived to golf courses and whether their drinking water came from groundwater sources, especially in regions vulnerable to groundwater contamination from pesticide or herbicide use.
The findings show that those living within one mile of a golf course had more than twice the odds of developing Parkinson's compared to those living more than six miles away.
The study also found that residents whose tap water was supplied from groundwater sources, particularly in regions prone to groundwater pollution, faced nearly twice the risk of developing Parkinson's if their water source was near a golf course.
While the study did not measure the type of pesticides used at the golf courses, the authors wrote that studies have linked pesticides used to treat golf courses with the development of PD. Examples of these pesticides include chlorpyrifos, 2,4-dichlorophenoxyacetic acid (2,4-D), Mancozeb (maneb), and so on.
Pesticides have been linked to nerve cell damage associated with Parkinson's, and are still commonly applied to golf courses to keep turf healthy and aesthetically pleasing.
Related Stories
4/6/2025
12/7/2024
These can enter the environment through runoff or groundwater
Parkinson's is progressive and currently has no cure. Risk of developing the degenerative condition increases with age, and most patients are diagnosed when more than 50 years old.
Dr. M. Maral Mouradian, distinguished professor of neurology and director of Rutgers Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and not involved in the study, told The Epoch Times that the study adds to growing evidence that environmental exposures may play a role in the disease's development.
An unrelated
This can be due to golf courses striving for a visually appealing, uniform appearance that can be achieved using large amounts of
pesticides to control weeds, insects, and diseases that could compromise this look.
'We were contacted by a golf community of approximately 2200 people because of a concern that PD was unusually prevalent in their community,' wrote the researchers of the 2020 study.
They discovered that among the multiple pesticides used on the golf course, there were three previously linked with Parkinson's risk: Mancozeb, 2,4-D, and manganese oxide.
Significant Limitations of the Study: Expert
Independent experts, not involved in the study, urge caution over interpreting the results.
Dr. Michael Genovese, physician and chief medical adviser at Ascendant New York, told The Epoch Times that researchers didn't directly measure pesticide exposure, such as testing people's blood or checking the water for chemicals.
'That means we cannot say pesticides caused the increase in Parkinson's,' he said. 'We can say that the results are very suspicious and match what other research has shown about pesticides being harmful to the brain.'
Professor David Dexter, director of research at Parkinson's UK, explained other significant limitations of the JAMA study in a
'Firstly, Parkinson's starts in the brain 10-15 years before diagnosis and the study didn't only use subjects who permanently lived in the area,' he said. 'This would not only affect participants' exposure, but also suggests their Parkinson's could have started before they moved around a golf course.'
Additionally, the population was not matched for location, with 80 percent of the Parkinson's subjects living in urban areas, compared to only 30 percent of controls, Dexter continued 'hence other factors like air pollution from motor vehicles, etc. could also account for some of the increases in Parkinson's incidence.'
Genovese said this study should still be considered a 'wake-up call,' even if it does not offer absolute proof. 'The pattern it shows is tough to ignore.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
3 days ago
- Epoch Times
Cowboys Owner Jerry Jones Announces He Is Cancer Free With New Treatment
Longtime Dallas Cowboys owner Jerry Jones, now cancer free, recently went public on his battle with Stage 4 melanoma via an interview with The Dallas Morning News and an upcoming Netflix series about the Cowboys that will air on Aug. 19. 'I was saved by a fabulous treatment and great doctors and a real miracle [drug] called PD-1 [therapy],' Jones told the paper. 'I went into trials for that PD-1, and it has been one of the great medicines. I now have no tumors.'
Business Wire
3 days ago
- Business Wire
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the three months ended June 30, 2025, as well as key recent clinical and corporate developments. 'Commercial and regulatory momentum for Multikine is accelerating due to three driving factors—our partnership negotiations in Saudi Arabia, the increasing interest in CEL-SCI from investors in the Middle East, and continued recognition in the global scientific and regulatory community that PD-L1 is a valuable predictive marker for head and neck cancer,' stated CEL-SCI CEO, Geert Kersten. 'We are particularly encouraged about the potential for Multikine to become commercially available in Saudi Arabia in 2025. Should this happen, we believe it could support our regulatory and commercial efforts worldwide.' Corporate and Clinical Developments include: CEL-SCI's CEO and a Director of the Company each purchased a combined total of 32,116 shares of restricted common CEL-SCI stock in July 2025. Gross proceeds of approximately $5.7 million were raised by CEL-SCI in July 2025 through the sale of 1,500,000 shares of common stock at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. In May of 2025, the Company raised gross proceeds of $5 million through the sale of 2,000,000 shares of common stock priced at $2.50 per share. CEL-SCI is set to sign a commercialization and regulatory partnership agreement with a leading Saudi Arabian pharmaceutical company for Multikine* (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in the Kingdom of Saudi Arabia. A Breakthrough Medicine Designation application for Multikine was filed by the pharma partner with the Saudi Food and Drug Authority (SFDA). According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in CEL-SCI, Multikine and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market. CEL-SCI's offering with Multikine is in line with Saudi Arabia's Vision 2030 initiative which seeks to make the Kingdom a global biotech hub. Given the SFDA's 60-day timeline to make Multikine potentially available, in-country investors have expressed interest in bringing a much-needed cancer treatment to market while also supporting their nation's health-tech goals. A new study supports CEL-SCI's strategy to seek early approval in the U.S. CEL-SCI is in final preparations before starting enrollment of its 212-patient Confirmatory Registration Study for Multikine in newly diagnosed locally advanced head and neck cancer patients. The U.S. Food and Drug Administration (FDA) has given CEL-SCI the go-ahead for the study. CEL-SCI plans to seek early approval based on early tumor responses. A third-party study recently published in Cancer Cell titled 'Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies' provides support for CEL-SCI's approach. The concept that tumor responses predict survival has been acknowledged for many cancer types and has led to accelerated approval of many cancer drugs. The third-party study published in Cancer Cell gives further support that this is also true in the neoadjuvant pre-surgical immunotherapy treatment of head and neck cancer. More data on PD-L1 as a predictive biomarker signals a clear regulatory pathway for Multikine in PLD-L1 negative patients. There is a growing body of data on PD-L1 as a predictive biomarker and diagnostic for cancer. In June, the FDA approved Merck's KEYTRUDA® (pembrolizumab), an anti-PD-L1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1. Of note, the FDA granted Merck priority review in February 2025 and approval in June 2025 based on interim results. This sets a positive precedent for Multikine in PD-L1 low and negative patients. Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by only 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival. Financial Results During the three months ended June 30, 2025, net loss available to common shareholders was $5.7 million compared to $7.5 million in the prior year period. Basic and diluted net loss per common share was $1.36 for the three months ended June 30, 2025, compared to $4.18 for the three months ended June 30, 2024. In demonstration of his deep commitment to the Company and Multikine's potential to significantly improve patient outcomes, CEO Geert Kersten has been and is currently working without taking a salary. About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy because that is the time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study of 928 patients, the FDA concurred with CEL-SCI's target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study which will enroll 212 patients. CEL-SCI will enroll newly diagnosed locally advanced not yet treated resectable head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing about 100,000 patients annually. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
Time Magazine
3 days ago
- Time Magazine
Kornelia Wieczorek: TIME's Girls of the Year List
Growing up, Kornelia Wieczorek, 17, wasn't interested in the sciences. 'I was scared of biology,' she says. 'I don't even know why.' It wasn't until a teacher showed her the many practical applications of biology that her love for the subject began to blossom. At the age of 10, she began taking classes at a nearby medical school and contributing to research labs. At 14, she and a friend co-created a biodegradable fertilizer using Rhizobium bacteria strains, that would promote seed growth without degrading soil. The invention—which she says could be cheaper than fertilizer on the market today—could be critical as the E.U. aims to reduce the amount of nitrogen fertilizer and pesticides in soil by 2030. Wieczorek hopes to conduct more detailed research on the fertilizer when she begins college, and has access to more advanced labs, next year. These days, Wieczorek's working on a number of projects—from an app to detect and diagnose skin changes, to research on the use of stem cells in therapies for Parkinson's, to creating an oncology app for brachytherapy in partnership with one of the biggest oncology centers in Poland. She's considering pursuing a dual degree—studying neuroscience and medicine—but the past few months have held so many opportunities that it's hard to know what the future might hold. 'I'm not really sure what will happen half a year from now, but I hope to be an expert in what I'm interested in, because it's something I really like.' She advises young scientists to wholeheartedly pursue the topics that interest them. 'Get as much knowledge as possible, and dare to incorporate it together, and to work on who you would like to be in the future.'
